Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

被引：11

作者：

Bar, Noffar ^{[1
,2
]}

Victoria Mateos, Maria ^{[3
]}

Ribas, Paz ^{[4
]}

Hansson, Markus ^{[5
,6
]}

Paris, Laura ^{[7
]}

Hofmeister, Craig C. ^{[8
]}

Rodriguez Otero, Paula ^{[9
]}

Aranzazu Bermudez, Maria ^{[10
]}

Martin, Thomas ^{[11
]}

Santoro, Armando ^{[12
,13
]}

Yee, Andrew J. ^{[14
]}

Creignou, Maria ^{[15
]}

Encinas Rodriguez, Cristina ^{[16
]}

Cerchione, Claudio ^{[17
]}

De La Rubia, Javier ^{[18
]}

Oriol, Albert ^{[19
,20
]}

Waibel, Heidi ^{[21
]}

Besemer, Britta ^{[22
]}

Thompson, Ethan ^{[23
]}

Kiesel, Brian ^{[23
]}

Chen, Jinjie ^{[23
]}

Chung, Alexander ^{[23
]}

Boss, Isaac W. ^{[23
]}

Gaudy, Allison ^{[23
]}

Li, Shaoyi ^{[23
]}

Hsu, Kevin ^{[23
]}

Godwin, Colin ^{[23
]}

Burgess, Michael R. ^{[23
]}

San-Miguel, Jesus ^{[9
]}

Costa, Luciano ^{[24
]}

机构：

[1] Yale Univ, Dept Internal Med, Sect Hematol, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Hosp Univ Dr Peset Aleixandre, Valencia, Spain

[5] Skane Univ Hosp, Lund, Sweden

[6] Sahlgrens Univ Hosp, Gothenburg, Sweden

[7] ASST Papa Giovanni XXIII, Bergamo, Italy

[8] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA

[9] Canc Ctr Clin Univ Navarra CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[10] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[11] Univ Calif San Francisco, San Francisco, CA USA

[12] Humanitas Univ, Milan, Italy

[13] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[14] Massachusetts Gen Canc Ctr, Boston, MA USA

[15] Karolinska Univ Hosp, Phase 1 Unit, Ctr Clin Canc Studies, Stockholm, Sweden

[16] Hosp Gen Univ Gregorio Maranon, IiSGM, Madrid, Spain

[17] Ist Sci Romagnolo Studio & Cura Tumori IRS IRCCS, Meldola, FC, Italy

[18] Univ Hosp La Fe, Valencia, Spain

[19] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[20] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[21] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen, Germany

[22] Univ Hosp Tuebingen, Tubingen, Germany

[23] Bristol Myers Squibb, Princeton, NJ USA

[24] Univ Alabama Birmingham, Birmingham, AL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[1] Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong, Sandy W.
Bar, Noffar
Paris, Laura
Hofmeister, Craig C.
Hansson, Markus
Santoro, Armando
Mateos, Maria-Victoria
Rodriguez-Otero, Paula
Lund, Johan
Encinas, Cristina
Yee, Andrew J.
Oriol, Albert
Cerchione, Claudio
de la Rubia, Javier
Ferstl, Barbara
Carlson, Kristina
Ribas, Paz
Bermudez, Arancha
Boss, Isaac W.
Gaudy, Allison
Li, Shaoyi
Hsu, Kevin
Godwin, Colin D.
Burgess, Michael R.
San-Miguel, Jesus
Costa, Luciano J.
BLOOD, 2022, 140
[2] Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA x CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
Costa, Luciano
Bar, Noffar
Mateos, Maria-Victoria
Ribas, Paz
Hansson, Markus
Paris, Laura
Hofmeister, Craig
Rodriguez-Otero, Paula
Bermudez, Maria Aranzazu
Santoro, Armando
Yee, Andrew
Creignou, Maria
Encinas, Cristina
Cerchione, Claudio
de la Rubia, Javier
Oriol, Albert
Ferstl, Barbara
Besemer, Britta
Chen, Jinjie
Boss, Isaac
Gaudy, Allison
Hsu, Kevin
Godwin, Colin
San-Miguel, Jesus
Wong, Sandy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S52 - S53
[3] Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models
Paiva, Bruno
Gaffney, Bonny
Burnett, Kelven
Castiglioni, Paola
La Motte-Mohs, Ross
Angelo, Michael
Pierce, Daniel
Boss, Isaac
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S46 - S47
[4] Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models
Paiva, Bruno
Gaffney, Bonny
Burnett, Kelven
Castiglioni, Paola
Angelo, Michael
Pierce, Daniel W.
Boss, Isaac W.
BLOOD, 2022, 140 : 7054 - 7055
[5] First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Costa, Luciano J.
Wong, Sandy W.
Bermudez, Arancha
de la Rubia, Javier
Mateos, Maria-Victoria
Ocio, Enrique M.
Rodriguez-Otero, Paula
San-Miguel, Jesus
Li, Shaoyi
Sarmiento, Rafael
Lardelli, Pilar
Gaudy, Allison
Boss, Isaac
Kelly, Lisa M.
Burgess, Michael R.
Hege, Kristen
Bensinger, William I.
BLOOD, 2019, 134
[6] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Garfall, Alfred L.
Usmani, Saad Z.
Mateos, Maria-Victoria
Nahi, Hareth
van de Donk, Niels W. C. J.
San-Miguel, Jesus F.
Rocafiguera, Albert Oriol
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Krishnan, Amrita
BLOOD, 2020, 136
[7] Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma
Voorhees, Peter
Shah, Nina
D'Souza, Anita
Rodriguez, Cesar
Weisel, Katja
Teipel, Raphael
Hurd, David
Bueno, Orlando
Pumford, Neil
Rosenberg, Tanya
Pothacamury, Rajvineeth Kumar
Ross, Jeremy
Polepally, Akshanth
Lee, Shane
Jin, Ziyi
Talati, Chetasi
Kumar, Shaji
Vij, Ravi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S34 - S34
[8] Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Costa, Luciano J.
Kumar, Shaji K.
Atrash, Shebli
Liedtke, Michaela
Kaur, Gurbakhash
Derman, Benjamin A.
Bergsagel, P. Leif
Mailankody, Sham
McCarthy, Philip L.
Limones, Josiana
Chen, Yanping
Das, Sharmila
Thorpe, Jerill
Cacciatore, Jonathan
Navarro, Garnet
Koegel, Ashley K.
Burgess, Michael R.
Hege, Kristen
Richard, Shambavi
BLOOD, 2022, 140 : 1360 - 1362
[9] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Krishnan, Amrita Y.
Garfall, Alfred L.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Nahi, Hareth
San-Miguel, Jesus F.
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Bhutani, Manisha
Karlin, Lionel
Benboubker, Lotfi
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Stephenson, Tara
Goldberg, Jenna D.
Banerjee, Arnob
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Kumar, Shaji
D'Souza, Anita
Shah, Nina
Rodriguez, Cesar
Voorhees, Peter M.
Bueno, Orlando F.
Ben Buelow
Freise, Kevin J.
Yue, Susan
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth R.
Vij, Ravi
BLOOD, 2021, 138

← 1 2 3 4 5 →